🇪🇺 irinotecan + Carboplatin + erbitux in European Union

irinotecan + Carboplatin + erbitux (irinotecan-carboplatin-erbitux) regulatory status in European Union.

Marketing authorisation

EMA

  • Status: approved

irinotecan + Carboplatin + erbitux in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is irinotecan + Carboplatin + erbitux approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for irinotecan + Carboplatin + erbitux in European Union?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.